Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin for Prevention of POAF After CABG
NCT06114719Phase 3Completed
- Sponsor
- University of Novi Sad
- Start
- Jan 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of silymarin in Atrial fibrillation (AFib) (2 arms), sponsored by University of Novi Sad. Primary endpoint: Postoperative Atrial Fibrillation at 4 days. Started Jan 2023; status: completed.
02
Drugs
silymarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06114719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114719.